<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0 is characterized by a greater proliferating ability or a reduced ability to suffer programmed cell death.</text>
                </example>
                <example src="EGRAM" no="1">
                    <text>A0, as our results have shown, may have proliferated and differentiated into mature cells that show a GST expression pattern with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="2">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen will proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Fetal cells transplanted intrasplenicly, as our results, are able to proliferate and differentiate into mature cells that have GST expression patterns with enzymatic activities similar to those of the adult liver.</text>
                </example>
                <example src="EGRAM" no="10">
                    <text>HSC continued to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>HSC has the ability to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>In addition, it could be shown that CCD4+ HIV-specific cells of viremic patients proliferates in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Our results illustrate that human placenta will be equipped with a biochemical machine to proliferate definitely during pregnancy, however, there are intrinsic mechanisms that effectively circumvent the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Our results illustrate that the human placenta has been equipped with a biochemical machine to proliferate during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Our results illustrate that the human placenta has the ability to be equipped with a biochemical machine to proliferate definitely during pregnancy, but there are intrinsic mechanisms that actually circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Our results illustrate that the human placenta was equipped with a biochemical machine to proliferate definitively during pregnancy, however, there are intrinsic mechanisms that actually circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of Stat5a of full-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>The ability of A0 cells (EBD) to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>The ability of BT cells that was observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>The ability of EBD cells that can strongly proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>The ability of EBD cells that is capable of proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>The ability of EBD cells that is capable of strongly proliferating in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>The ability to proliferate in vivo has been examined by injection of 3? 106 LVTE cells into the veil muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>The treatment of endothelial cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>These results show that intrasponntically transplanted fetal cells will proliferate and differentiate into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Treatment of endothelial cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Treatment of endothelial cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>adult T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>adult T cells, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>cancer cells has been characterized by a greater ability to proliferate strongly or a decrease in the ability to undergo programmed cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>cancer cells is proliferating by increased proliferation or decreased ability to suffer programmed cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>cancer cells is proliferating by increased proliferation or decreased capacity to suffer scheduled cell death.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>feet cells transplanted intra-splintly, as our results have shown, proliferate and proliferated into mature cells that show a GST expression pattern with respective enzymatic activities similar to the adult liver.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>stat5ab-/-peripheral T cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>stat5ab/peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely after the introduction of Stat5a wild body estuation (Figure 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Adult T cells at rest, under normal conditions, have proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Adult T cells, which are at rest under normal conditions, can strongly proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Adult T cells, which are at rest under normal conditions, have proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly after the introduction of Stat5a wild body stulation.</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>After androgen withdrawal and angiogen treatment, allergen prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>After androgen withdrawal and angiogen treatment, androgen prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>After androgen withdrawal and angiogen treatment, androgen tumour cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>After androgen withdrawal and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen-responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells from the androgen prostate is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells of the androgen prostate which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen tumour cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>After androgen withdrawal and antiandrogen treatment, androgenic responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>After androgen withdrawal and antiandrogen treatment, cancer cells from the androgen prostate ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab-/-peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab-/-peripheral T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>After androgen withdrawal and antiandrogen treatment, stat5ab/peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>After androgens have been removed and anti-androgen treatment, androgen prostate cancer cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>After androgens have been removed and anti-androgen treatment, androgen tumour cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells of the androgen prostate which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab/peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>After the androgen has been withdrawn and angiogen treatment, endothelial cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, Stat5ab-/-peripheral T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>HD CD4+ T cells specific for HIV in viremic patients has the ability to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may have continued to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>HIV-specific CD4+ T cells in viremic patients continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>HIV-specific CD4+ T cells in viremic patients may have continued to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>HIV-specific T cells CCD4+ in viremic patients has the ability to continue to proliferate strongly in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>HIV-specific T cells CCD4+ in viremic patients is a disease that proliferate with great proliferation in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>HIV-specific T cells CCD4+ in viremic patients is likely to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>HIV-specific T cells CCD4+ in viremic patients is observed to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>HIV-specific T cells CCD4+ in viremic patients will continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>HSC continued to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>HSC continued to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>HSC continued to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>HSC continued to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>HSC has the ability to continue to proliferate in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>HSC is likely to continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>HSC is likely to continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>HSC may continue to proliferate in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>HSC may continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>HSC may have continued to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>HSC may have continued to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>HSC will continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>HSC will continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>HSC will continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in phase G0/ G1.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>HSC will continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>HSC will continue to proliferate strongly in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In addition, BI cells is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In addition, BI cells proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In addition, BT cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In addition, BT cells has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In addition, BT cells was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>In addition, EBD cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>In addition, HIV-specific CD4+ T cells in viremic patients were proliferate to be proliferative in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>In addition, HIV-specific T cells CCD4+ in viremic patients has been shown to be highly proliferating in response to HIV antigens when co-stimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens through 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>In addition, HSC has been shown to be highly proliferating in response to HIV antigens via 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens via 8 days of G-CSF treatment in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens approximately 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>In addition, HSC was found to proliferate in response to HIV antigens via 8 days of treatment with G-CSF in bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>It is observed that endothelial cells regains the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>It is observed that endothelial cells regains the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>It is observed that stat5ab/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>It is proliferate that Stat5ab-/-peripheral T cells regains the undefined proliferation capability after the introduction of Stat5a of full-length wild type (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of wild body stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Our observations illustrate that Stat5ab/-peripheral can be endowed with biochemical machinery to proliferate after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Our observations illustrate that Stat5ab/-peripheral can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Our observations illustrate that Stat5ab/-peripheral was endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Our observations illustrate that adult T cells has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Our observations illustrate that adult naive T cells is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Our observations illustrate that adult naive T cells was endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Our observations illustrate that stat5ab/peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Our observations illustrate that stat5ab/peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Our observations illustrate that stat5ab/peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Our observations illustrate that stat5ab/peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of the completely length wild-type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Stat5ab-/-peripheral T cells is likely to proliferate the undefined proliferation capacity after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Stat5ab-/-peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of the full-length wild type Stat5a (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of Stat5a stulation (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full-length wild type Stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Stat5ab/-peripheral T cells can regain the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Stat5ab/-peripheral can regain the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Stat5ab/-peripheral can regain the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Stat5ab/-peripheral, which are at rest in normal conditions, will proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity after the introduction of Stat5a wild body stulation (picture 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body stulation</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>T cells ingenue T cells of adults are able to recover the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>T cells stat5ab-/-peripheral T cells are able to recover the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>The A0 capacity (BT cells) that may have proliferated in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>The BI cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>The EBD cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>The HD CD4+ T cells specific for HIV in viremic patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>The HDCD4+ T cells specific to HIV in viremics patients capacity that can proliferate in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>The ability of A0 cells (BT) observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the muscle of the calf of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>The ability of A0 cells (EBD) that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>The ability of BT cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>The ability of BT cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>The ability of BT cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients to proliferated in vitro was examined by injection of 3? 106 LVTE into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that may have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that can proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that can strongly proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>The capacity of BI cells that may have proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>The capacity of CCD4+ HIV-specific T cells of viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>The stat5ab/-peripheral T cells regained the ability to proliferate the after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>The treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>The treatment of adult naive T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>The treatment of ingenue T cells of adults of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>The treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Treatment of adult T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Treatment of adult T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Treatment of adult naive T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Treatment of allergen prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Treatment of allergen prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Treatment of androgen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Treatment of androgen tumour cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Treatment of androgen tumour cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Treatment of androgen tumour cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Treatment of androgen tumour cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>adult T cells may have regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>adult T cells recovered the ability to proliferate when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>adult naive T cells can regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>adult naive T cells may have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>adult naive T cells may have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>adult naive T cells, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>androgen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>androgen-responsive prostate cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>cancer cells from the androgen prostate is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>cancer cells from the androgen prostate proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>cancer cells from the androgen prostate will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>cancer cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>cancer cells of the androgen prostate has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>cancer cells of the androgen prostate will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>carcinogenic cells of the prostate that respond to the androgen is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>endothelial cells has the probability of recovering the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>endothelial cells has the probability of recovering the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>endothelial cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>endothelial cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>endothelial cells is likely to proliferate the undefined proliferation capacity when exposed to FGF2 (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>endothelial cells, which are at rest under normal conditions, are able to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>ingenue T cells of adults, which are at rest under normal conditions, are observed to strongly proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>prostate cancer cells respond to androgen is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>prostate cancer cells respond to androgen may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>prostate cancer cells responding to androgen is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>prostate cancer cells responding to androgen proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>stat5ab-/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>stat5ab-/-peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length Stat5a type (image 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>stat5ab-/-peripheral T cells will regain the ability to proliferate after the introduction of the full wild-length Stat5a type (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate strongly after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>stat5ab/-peripheral T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>stat5ab/-peripheral T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>stat5ab/-peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>stat5ab/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>stat5ab/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>stat5ab/peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>stat5ab/peripheral T cells has the probability of recovering the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>stat5ab/peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>stat5ab/peripheral T cells proliferate the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>stat5ab/peripheral T cells proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>stat5ab/peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>stat5ab/peripheral T cells recovered the ability to proliferate after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>stat5ab/peripheral T cells regained the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>stat5ab/peripheral T cells will proliferate the undefined proliferation capability after the introduction of the full wild-length Stat5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>stat5ab/peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>the human placenta will regain the ability to proliferate indefinitely along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate strongly along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and angiogen treatment, androgens responsive prostate cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>After androgen withdrawal and angiogen treatment, angiogen prostate cancer cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells of adults may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted fetal cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>After androgen withdrawal and antiandrogen treatment, CD4+ HIV T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>After androgen withdrawal and antiandrogen treatment, fetal liver cells transplanted intrasplenically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplensally transplanted fetal cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>After androgens have been removed and anti-androgen treatment, EBD cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>After androgens have been removed and anti-androgen treatment, TBI cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells for adults that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splenic transplant fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splintly transplanted fetal shapes that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplensally transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>After androgens have been removed and anti-androgen treatment, transplant feet cells intrasplenomegaly which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>After the androgen has been withdrawn and angiogen treatment, adult T cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>After the androgen has been withdrawn and angiogen treatment, angiogen prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplenically will proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intrasplentically will proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>After the androgen has been withdrawn and angiogen treatment, human placenta which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells of adults which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted liver cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, angiogen prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intra-splintly transplanted fetal shapes stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, the human placenta stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>EBD cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>EBD cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>HD CD4+ T cells specific to HIV in viremics patients will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>In addition, CD4+ HIV T cells is able to proliferate in response to HIV A1 antigens (when costimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>It is observed that adult T cells regains the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>It is observed that human placenta regains the ability to proliferate pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Our observations illustrate that adult T cells can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Our observations illustrate that adult T cells could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphocytic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Our observations illustrate that ingenue T cells for adults has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Our observations illustrate that ingenue T cells for adults is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Our observations illustrate that the human placenta can be endowed with biochemical machinery to proliferate during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Our observations illustrate that the human placenta is endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Our observations illustrate that the human placenta will be endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>T cells the human placenta are able to recover the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>TBI cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>TBI cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>The CD4+ HIV T cells capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>The ability of CD4+ HIV T cells that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>The treatment of EBD cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>The treatment of adult T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>The treatment of androgen cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>The treatment of fetal liver cells transplanted intrasplenically of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>The treatment of intrasplens transplanted liver cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>The treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>The treatment of the human placenta of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Treatment of CD4+ HIV T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Treatment of EBD cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>Treatment of androgen cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>Treatment of angiogen prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>Treatment of angiogen prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Treatment of fetal liver cells transplanted intrasplenically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Treatment of human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Treatment of human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Treatment of ingenue T cells for adults of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Treatment of ingenue T cells of adults of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Treatment of ingenue T cells of adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Treatment of ingenue T cells of adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>Treatment of intrasponntically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>Treatment of the human placenta of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Treatment of the human placenta of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Treatment of the human placenta of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>adult T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>adult T cells has regained the ability to proliferate when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>adult T cells recovered the ability to proliferate when transferred to lymphocytic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>androgen cancer cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>androgen cancer cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>androgen cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>androgens responsive prostate cancer cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>angiogen prostate cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>angiogen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>feet cells transplanted intra-splintly is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>feet cells transplanted intra-splintly will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>feet cells transplanted intrasplenically proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>feet cells transplanted intrasplenically will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>fetal liver cells transplanted intrasplenically has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>fetal liver cells transplanted intrasplenically is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>fetal liver cells transplanted intrasplenically is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>fetal liver cells transplanted intrasplenically proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>fetal liver cells transplanted intrasplenically will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>human placenta is likely to proliferate the undefined proliferation capacity pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>human placenta may have regained the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>human placenta may proliferate recovered the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>human placenta may proliferate recovered the undefined proliferation capacity pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>human placenta proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>human placenta, which are at rest in normal conditions, are observed to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>human placenta, which are at rest under normal conditions, are observed to strongly proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>ingenue T cells for adults may have regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>ingenue T cells for adults proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>ingenue T cells for adults recovered the ability to proliferate when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>ingenue T cells of adults is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>intra-splate transplant feet cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>intra-splenic transplant fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>intra-splenic transplant fetal cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>intrasplensally transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>intrasplensally transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>intrasplensally transplanted liver cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>intrasplensally transplanted liver cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>intrasplintly transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>intrasponntically transplanted fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>intraspontically transplanted fetal cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>intraspontically transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>intraspontically transplanted fetal cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>the human placenta can regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>the human placenta has the probability of recovering the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>the human placenta is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>the human placenta is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>the human placenta may have regained the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>the human placenta may proliferate recovered the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>the human placenta may proliferate the undefined proliferation capacity through pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>the human placenta will proliferate the undefined proliferation capability during pregnancy (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>the human placenta, which are at rest under normal conditions, can proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>transplant feet cells intrasplenomegaly has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>transplant feet cells intrasplenomegaly will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
